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Abstract
BACKGROUND: The presence of gene polymorphisms in the renin-angiotensin-aldosterone system associated with 
an impaired endothelial function that causes atherosclerosis and also myocardial fibrosis such as the polymorphism 
of the angiotensin-converting enzyme gene and the angiotensin I receptor (AT1R) gene.
AIM: This research was aimed to explore the role of AT1R A1166C gene polymorphism in the incidence of coronary 
slow flow phenomenon (CSFP) in the Malay population, South Sumatra, Indonesia.
METHODS: This study is a comparative analysis using a case-control study design to analyze the effect of the AT1R 
A1166C gene polymorphism on the incidence of slow flow phenomenon in patients undergoing elective coronary 
angiography at Mohammad Hoesin Hospital Palembang, Indonesia. Examination of AT1R gene polymorphism was 
carried out with several steps starting from deoxyribonucleic acid extraction, polymerase chain reaction process, 
followed by restriction fragment length polymorphism stages with Ddel restriction enzymes and visualization.
RESULTS: Thirty-two patients participated in these study-baseline characteristics between homogeneous coronary 
regular flow groups and homogeneous coronary slow flow groups. There is no difference between genotype 
distribution, allele frequency, and genotype between the CSFP and the coronary standard flow group.
CONCLUSION: There is no influence of AT1R A1166C gene polymorphism on the CSFP in patients undergoing 
coronary angiography.
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Introduction
The phenomenon of angina chest pain 
without significant epicardial coronary artery stenosis 
but accompanied by a slowing of coronary blood flow 
attracts cardiologists since the era of invasive coronary 
angiography [1]. The phenomenon of slow coronary 
blood flow is commonly known as the coronary slow 
flow phenomenon (CSFP) [2]. In 1972, Ghanie et al. at 
Dr. Mohammad Hoesin Hospital began to observe this 
phenomenon starting in 2003 intensively [3]. Most of the 
published research defines CSFP using the thrombolysis 
in myocardial infarction criteria introduced by Gibson. 
Categorized as CSFP if the time needed to contrast to 
pass at least one of the three branches of the coronary 
arteries to the distal marker is more than twenty-seven 
frames without a significant stenosis lesion (<40%) [4]. In 
contrast, Ghanie et al. took the CSFP limit using the time 
blanking criteria contrast (clearance) in the left anterior 
descending (LAD) artery. CSFP is categorized if the time 
of the entry of the contrast media starts from the LAD 
artery estuary until the disappearance of the contrast in 
the distal branch is more than 45 frames (in <3 s) [3].
Various studies that reported the prevalence 
of CSFP varied between 17% [4], [5], [6], [7] The 
majority of CSFP was relatively high, at 38.3% reported 
by Ghanie et al. at Dr. Moh Hoesin general hospital, 
Palembang, Indonesia [3], [4]. About 80% of CSFP 
patients experienced recurring or persistent symptoms 
such as discomfort in the chest, tightness, and chest 
pain. Some clinical studies report that the long-term 
prognosis of most CSFP patients is quite good, but 
some patients develop acute myocardial infarction, 
rhythm disorders, and sudden cardiac death [5], [8].
So far, the pathophysiology of CSFP is not exact; 
it is thought to be caused by various causes in blood 
vessels, in the form of coronary microvascular disease, 
inflammation and endothelial dysfunction [9], [10], [11]. 
The pathogenesis of CSFP also involves a vital role 
of the renin-angiotensin-aldosterone system (RAAS). 
This system consists of hormones and enzymes, 
which include angiotensinogen, angiotensin-converting 
enzyme (ACE), angiotensin I (AT1), angiotensin II 
(AT2), and aldosterone. AT2 has two receptor subtypes, 
namely, type 1 receptor (AT1R) and type 2 receptors 
(AT2R) [10]. The function of AT2 not only to stimulating 
aldosterone secretion but also to constrict blood vessel, 
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stimulates various growth factors, initiates hypertrophy 
and smooth muscle hyperplasia of blood vessels, 
making the condition of arterial stiffness. Besides, 
AT2 also oxidizes low-density lipoproteins cholesterol 
particles so that it starts absorption into the endothelium 
which will cause endothelial dysfunction, which results 
in atherosclerosis of the epicardial coronary arteries as 
well as small arteries and capillaries that connect with 
small veins [5], [12].
Several studies indicate the presence of gene 
polymorphisms in RAAS associated with an impaired 
endothelial function that causes atherosclerosis and 
also myocardial fibrosis such as the polymorphism of the 
ACE gene and the AT1R gene. So that the ACE gene and 
the AT1R gene become candidate genes as a cause of 
cardiovascular disease, including CSFP [12], [13], [14], 
this study is the first study that seeks to explore the role 
of AT1R A1166C gene polymorphism in the incidence 
of CSFP in the population of Malay, South Sumatra, 
Indonesia.
Methods
This study is a comparative analysis using a 
case-control study design to analyze the effect of the 
AT1R A1166C gene polymorphism on the incidence 
of CSFP in patients undergoing elective coronary 
angiography at Mohammad Hoesin Hospital Palembang, 
Indonesia. The study subjects were all patients indicated 
to have coronary angiography that fulfilled the inclusion 
and exclusion criteria, where the sampling was done 
in a consecutive sampling method until groups with 
CSFP and without CSFP were collected, respectively, 
32 people, with matching for age and sex. Inclusion 
criteria were aged more than 18 years old, willing to 
participate in the study and signed informed consent, 
the group of cases obtained slowing down of coronary 
blood flow based on clearance criteria of more than 45 
frames (more than 3 s) in the LAD artery, the control 
group found coronary blood flow ≤45 frames (≤3 s) in 
the LAD artery. Exclusion criteria were subjects with 
systolic heart failure (ejection fraction <50%), valvular 
heart disease, patients with connective tissue disease 
and autoimmune disease, patients with liver disease, 
and severe renal impairment. The ethics committee 
approved this study of the Faculty of Medicine of 
Sriwijaya University No. 234/kptfkunsri-rsmh/2019.
Examination of AT1R gene polymorphism 
was carried out with several steps starting from 
deoxyribonucleic acid (DNA) extraction, polymerase 
chain reaction (PCR) process, followed by restriction 
fragment length polymorphism (RFLP) stages with Ddel 
restriction enzymes and visualization. DNA extraction 
begins with as much as 200 uL of blood inserted in a 
sterile 1.5 mL tube. Washed with phosphate-buffered 
saline (PBS) pH 7.4 of 1000 uL then centrifuged at a 
speed of 5000 rpm for 5 min. Supernatant removed, 
this stage is repeated up to 2–3 times. Supernatant 
removed and then added 500 μL of saponin 0.5% 
mixed using a vortex—deep incubation for 24 h in the 
refrigerator –20°C. Vortex returns to melt immediately, 
then centrifuge at 12,000 rpm for 10 min, discard 
the supernatant. Add PBS 10,000 uL, centrifuge at 
5000 rpm for 10 min, and remove the supernatant. They 
were repeated 2 times until the supernatant is clear.
The supernatant is removed then added 50 μL 
of Chelex (chelating agent) and added 100 μL of dd 
H2O. Incubated/boiled in boiling water for 5 min then 
homogenized. Centrifuge with a speed of 1000 rpm 
for 1 min. Set in boiling water for 10 min. Centrifuge at 
12,000 rpm for 10 min. DNA will be in the supernatant 
(DNA containing water), then the supernatant part is 
removed in a sterile tube and stored at –20°C until 
PCR examination. The PCR stage is an initial process 
of denaturation for 5 min at a temperature of 95°C. 
Then, it will be followed by denaturation at 94°C for 
30 s for 34 cycles, annealing at 58°C for 1 min, and 
extension at 72°C for 35 s. The results of the products 
which have been applied were visualized with 
agarose gel 2% dipped with ethidium bromide. The 
next step is making RFLP mix with ingredients such 
as dd H2O 3.5 mL, a buffer of 1 ML, enzyme 0.5 ML, 
10 ML amplicon with a total of 15 ML. Furthermore, 
incubation was carried out for 3 h, and the results of 
the product carried out by cutting the Ddel enzyme 
were visualized with agarose gel 2% dipped with 
ethidium bromide.
Genetic analysis of the AT1R A1166C gene 
polymorphism in the 3’UTR region used 5’AAT GCT 
TGT AGC CAA AGT CAC CT 3 as primary sense (F) 
and 5’GGC TTT GCT TTG TCT TGT TG 3’ as primary 
antisense (R). The PCR results are 856 base pairs 
(bp) cuts. After being cut with the Ddel RFLP enzyme 
for 3 h, the PCR product was detected in the presence 
of electrophoretic spots on the 2% agarose gel with 
ethidium bromide. A homozygous allele produces two 
fragments referring to the size of 600 bp and 256 bp. The 
mutant C allele has three fragments, 600 bp, 146 bp, and 
110 bp. Individual homozygous A alleles will produce 
two bands, 600 bp and 256 bp. Individual homozygous 
C alleles will have three rounds, namely 600 bp, 146 bp, 
and 110 bp. AC heterozygous individuals produce four 
bands, namely, 600 bp, 256 bp, 146 bpm, and 110 bp.
Data management and analysis are performed 
using the SPSS 25.0 for Windows program. Data are 
presented in the form of narratives and tables. To 
determine the normality of the data, the Shapiro–Wilk 
distribution test was conducted. Information is generally 
distributed if the value of p > 0.05. Hypothesis testing 
in this study was carried out using the Chi-square test 
if the Chi-square test requirements were not met; it was 
carried out by the Fisher’s exact test.
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Results
Table 1 shows that clinical and laboratory 
characteristics between the CSFP group and the 
coronary normal flow (CNF) group were not statistically 
significant differences, p > 0.05. Table 1 shows that 
the subjects used in this study are homogeneous 
to minimize the presence of confounding factors 
that will influence the genetic analysis of AT1R gene 
polymorphisms.
Table 1: Baseline characteristics
Characteristics CSFP CNF p
Age (Mean ± SD) 50.6 ± 7.7 52.5 ± 12.4 0.31**
Gender
Male, n (%) 20 (62.5) 18 (56.3) 0.35*
Female, n (%) 12 (37.5) 14 (43.7)
Smoking
Yes, n (%) 9 (28.1) 14 (43.7) 0.37*
No, n (%) 23 (71.9) 18 (56.3)
Hypertension
Yes, n (%) 18 (56.2) 18 (56.2) 0.9*
No, n (%) 14 (43.8) 14 (43.8)
Diabetes mellitus
Yes, n (%) 7 (21.9) 7 (21.9) 0.9*
No, n (%) 25 (78.1) 25 (78.1)
Body mass index
<25 kg/m2 18 (56.2) 18 (56.2) 0.9*
≥25 kg/m2 14 (43.8) 14 (43.8)
ACEI/ARB consumption
Yes, n (%) 9 (28.1) 9 (28.1) 0.9*
No, n (%) 23 (71.9) 23 (71.9)
Anti-diabetic drugs
Yes, n (%) 3 (9.4) 2 (6.3) 0.7*
No, n (%) 29 (90.6) 30 (92.7)
Statin consumption
Yes, n (%) 6 (18.8) 5 (15.6) 0.7*
No, n (%) 26 (81.2) 27 (84.4)
Aspirin consumption
Yes, n (%) 12 (37.5) 18 (56.3) 0.5*
No, n (%) 20 (67.5) 14 (42.8)
Clopidogrel consumption
Yes, n (%) 5 (15.6) 8 (25) 0.6*
No, n (%) 27 (84.4) 24 (75)
Hb (Mean ± SD) 13.9 ± 1.8 13.36 ± 1.5 0.6**
Leukocyte (Mean ± SD) 8.2 ± 1.1 8.3 ± 1.5 0.6**
Thrombocyte (Mean ± SD) 293.8 ± 55.3 289.9 ± 
57.8
0.6**
Ureum (Mean ± SD) 23.9 ± 5.8 25.3 ± 5.5 0.5**
Creatinine (Mean ± SD) 0.89 ± 0.41 0.83 ± 0.45 0.6**
Blood glucose (Mean ± SD) 113.9 ± 45.5 112.4 ± 34.8 0.6**
Cholesterol (Mean ± SD) 153.9 ± 23.8 154.4 ± 
18.3
0.3**
CSFP: Coronary slow flow phenomenon, CNF: Coronary normal flow, *Chi-square test, p < 0.05; 
**Independent t-test, p < 0.05
The genetic analysis presented in Table 2 shows 
that the distribution of genotypes, allele frequencies, 
and genotypes between the CSFP and CNF groups was 
not different. This difference is increasingly seen where 
the statistical tests show that there is no significant 
difference between the CSFP and CNF groups in the 
AC/CC and AA genotype frequencies.
Discussion
The condition of CSFP is the interaction 
of various pathophysiological pathways involving 
traditional risk factors, genetic factors, and RAAS 
components. The role of RAAS in the pathogenesis 
of CSFP is quite significant. The variation of genes 
encoding functional proteins plays a role in influencing 
the activity of the RAAS pathway. Several studies have 
reported that the RAAS gene encoding component is a 
candidate gene in cardiovascular disease, the presence 
of RAAS gene polymorphisms associated with coronary 
artery disease, including CSFP events [15], [16], [17]. 
The effect of AT1R gene polymorphisms on CSFP 
events is not yet apparent, and research has limited 
the influence of AT1R A1166C gene polymorphism 
on coronary microvascular circulation, which causes 
CSFP [18], [19], [20], [21]. There are genetic variations 
on the tendency to experience CSFP in various ethnic 
groups. Several studies report the presence of gene 
polymorphisms in groups with coronary artery disease 
and experiencing microvascular dysfunction with groups 
that have healthy coronary arteries both anatomically 
and functionally. These studies conclude that there 
may be a relationship between gene polymorphisms 
with ischemic heart disease in this case against vessel 
disease coronary blood and microvascular dysfunction. 
In several studies, it is suspected that the presence of 
C allele in the AT1R gene will increase the detrimental 
effects of AT2 [22], [23], [24], [25].
In this study, the dominant genotype AA and 
allele A distribution were obtained. There is not much 
difference in genotype distribution and allele frequency 
of CSFP groups and CNF groups. From the analysis, 
there was no correlation between AT1R A1166C gene 
polymorphism and CSFP events. As is known, AT1R 
gene expression in individuals with A allele is not too 
large. In contrast, in this study, the dominant allele A 
frequency is obtained so that the adverse effects of 
AT2 in the form of vasoconstriction, hypertrophy, and 
hyperplasia and extracellular matrix deposition are 
not so significant. It is suspected that the influence of 
aldosterone is the leading cause of CSFP events; the 
study of Ghanie et al. supports this. In which a significant 
relationship was found between aldosterone levels and 
the incidence of CSFP. This relation is evidenced by the 
high prevalence of diastolic dysfunction in this study, 
but unfortunately, in this study, we did not examine 
aldosterone and AT2 levels [26], [27], [28], [29]. Ghanie 
also reported, based on genotype analysis, the majority 
of CSFP patients had genotype ii, which showed that 
ACE enzyme activity was low, so it cannot explain high 
aldosterone concentrations via the ACE pathway. The 
non-ACE pathway may have a role in the conversion of 
AT1 to AT2 and elevated aldosterone [3]. Besides, the 
coronary microvascular at the capillary level, it is only 
covered by the endothelium and basement membrane 
Table 2: Genetic analysis of AT1R gene polymorphism
Genetic analysis CSFP, n (%) CNF, n (%) p*
Genotype distribution
AA 25 (78.1) 26 (81.25)
AC 6 (18.8) 6 (18.75)
CC 1 (3.1) 0
Allele Frequency
A 56 (87.5) 58 (90.6)
C 8 (12.5) 6 (9.4)
Genotype
AC/CC 7 (21.9) 6 (18.75) 0.76
AA 25 (78.1) 26 (81.25)
CSFP: Coronary slow flow phenomenon, CNF: Coronary normal flow, *Chi-square test, p < 0.05. 
AT1R: Angiotensin I receptor
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where there is no AT1R receptor. Distribution of AT1 
receptors were mostly in smooth muscle, and tunica 
adventitia of arteries. If CSFP disturbance is suspected 
to occur at the level of capillaries that are only covered 
by the endothelium, there is no role of AT2 through 
type-1 [30], [31], [32] receptors. The study of Ghanie 
et al. also supports this (homocysteine and adiponectin) 
in both CSFP and NSF patients, so the possible cause 
is not in the presence of endothelial dysfunction [3].
While in the myocardium, the AT1 receptor 
distribution is found with low density in the atria and 
ventricles so that the role of AT1R makes hypertrophy, 
hyperplasia, and pro-fibrosis less pronounced large so 
that can be used as an excuse is an increase in aldosterone 
levels through the non-ACE pathway [3], [33] Besides, 
the existence of treatment with ACE-inhibitors can affect 
due to an increase in the effects of bradykinin [34].
The research reported by Yalcin et al. also 
found no association between AT1R A1166C gene 
polymorphisms and CSFP events, Yalcin et al. could 
not conclude the role of AT1R on CSFP events [15]. 
Other studies looked at the effect of AT1R A1166C 
gene polymorphisms with cardiovascular events, as 
reported by Delshad et al. the relationship between the 
AT1R A1166C gene polymorphism and the incidence 
of acute coronary syndromes [35], [36]. The study 
reported by Araujo et al. found no relationship between 
the polymorphism of the AT1R A1166C gene with the 
incidence of acute myocardial infarction or the severity 
of coronary artery disease [36].
The study reported by Mishra et al. AC and CC 
were significantly higher in patients who experienced 
impaired left ventricular function compared with those 
who did not experience impaired left ventricular 
function. Further analysis showed that there was a 
significant relationship between the polymorphism 
of the AT1R A1166C gene with the dimensions of left 
ventricular (LV) end-diastole and LV end-systole and 
LV ejection fraction.[20] Based on these studies, the 
influence of genetic factors did not stand on CSFP or 
cardiovascular events, but other factors contributed to 
the CSFP incident [30], [31], [32].
Besides the influence of RAAS, the mechanical 
condition of myocardial hypertrophy also contributes to the 
high level of resistance at the microcirculation level as found 
in the mean height experienced hypertrophy in the CSFP 
group. The presence of comorbid in the form of traditional 
risk factors contributes to the destruction of endothelium 
physiology and the perivascular environment, which 
activates complex molecular pathways. This condition 
ultimately contributes to myocardial fibrosis which results 
in ventricular stiffness and diastolic dysfunction that is 
often found in CSFP patients [33]. Besides, these other 
pathophysiological processes may underlie CSFP is an 
increase in coronary microvascular resistance caused 
by microvascular endothelial dysfunction associated 
with atherosclerosis diffuse, thus resulting in stiffness in 
arterioles and coronary capillaries [34], [35].
Due to its difficulty in histology examination, the 
coronary microvascular circulation is still a mystery outside 
the epicardial arteries. With an understanding of the 
interaction between genetic influences, RAAS, metabolic 
disorders, and humoral components in the microvascular 
circulation that play a role in the mechanism of CSFP could 
assist in the development of diagnostic and therapeutic 
strategies. Until now, not many studies have tried to find the 
correlation of genetic factors and biochemical components 
with the incidence of CSFP. Ghani’s research shows the 
influence of ACE gene polymorphisms on CSFP events, 
but there is no relationship with inflammation [3]. Since the 
pathophysiology and role of genetic factors in CSFP are 
not yet fully known, so far, the treatment of CSFP has not 
been satisfactory.
The target of therapy is aimed at functional 
obstruction in arterioles (<200 μm), such as 
dipyridamole, which has a vasodilator effect on 
coronary microvascular. Furthermore, administration 
of long-acting mibefradil (calcium T-channel antagonist 
group) gives a good response to microvascular. 
Provision of statins (such as simvastatin and 
atorvastatin) which have anti-inflammatory effects 
on blood vessels to improve endothelial function 
can relieve symptoms in CSFP. Administration of 
potentiation beta-blocker nebivolol 5 mg daily for 12 
weeks can improve endothelial function in CSFP 
patients. The administration of anti-angina nicorandil 
drug, which has a vasodilator effect by increasing 
cGMP 5 mg three times a day can reduce episodes 
of chest pain and improve left ventricular function in 
CSFP patients. This effect may be due to an increase in 
NO expenditure and a decrease in endothelin-1 levels. 
Besides, trimetazidine antianginal drugs which work to 
inhibit the oxidation of beta fatty acids can reduce the 
symptoms of angina in CSFP patients [35]. Prognosis 
of CSFP patients at the age of 50 years with comorbid 
hypertension and dyslipidemia is not right. Therefore 
CSFP should be considered a separate disease and 
CSFP quite dangerous [6], [36].
Conclusion
There is no influence of AT1R A1166C gene 
polymorphism on the CSFP in patients undergoing 
coronary angiography.
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